FSSNX
Price
$37.30
Change
-$0.36 (-0.96%)
Updated
Jun 23 closing price
Net Assets
34B
VYSGX
Price
$16.56
Change
-$0.12 (-0.72%)
Updated
Jun 23 closing price
Net Assets
192.63M
Interact to see
Advertisement

FSSNX vs VYSGX

FSSNX vs VYSGX Comparison Chart in %
View a ticker or compare two or three
VS
FSSNX vs. VYSGX commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSSNX is a StrongBuy and VYSGX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FSSNX has more cash in the bank: 34B vs. VYSGX (193M). FSSNX pays higher dividends than VYSGX: FSSNX (0.92) vs VYSGX (0.54). FSSNX was incepted earlier than VYSGX: FSSNX (15 years) vs VYSGX (17 years). VYSGX (0.92) is less costly to investors than FSSNX (0.03). VYSGX is a more actively managed with annual turnover of: 179.00 vs. FSSNX (14.00). FSSNX has a lower initial minimum investment than VYSGX: FSSNX (0) vs VYSGX (1000). FSSNX annual gain was more profitable for investors over the last year : 42.83 vs. VYSGX (18.31). FSSNX return over 5 years is better than : 34.97 vs. VYSGX (-11.87).
FSSNXVYSGXFSSNX / VYSGX
Total Expense Ratio0.030.923%
Annual Report Gross Expense Ratio0.030.923%
Fund Existence15 years17 years-
Gain YTD21.75916.725130%
Front LoadN/AN/A-
Min. Initial Investment01000-
Min. Initial Investment IRAN/AN/A-
Net Assets34B193M17,617%
Annual Yield % from dividends0.920.54170%
Returns for 1 year42.8318.31234%
Returns for 3 years72.4529.51246%
Returns for 5 years34.97-11.87-295%
Returns for 10 years169.5013.451,260%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VCBCX18.91N/A
N/A
VALIC Company I Systematic Growth
ESPIX41.02N/A
N/A
Allspring Special Small Cap Value Adm
HSFNX30.52N/A
N/A
Hennessy Small Cap Financial Investor
TRULX46.30N/A
N/A
T. Rowe Price US Large-Cap Core
BRUHX18.32N/A
N/A
MFS Blended Research Value Equity I